Audentes Therapeutics (BOLD) Downgraded by BidaskClub to Buy

BidaskClub lowered shares of Audentes Therapeutics (NASDAQ:BOLD) from a strong-buy rating to a buy rating in a report released on Tuesday morning, BidAskClub reports.

Several other analysts also recently issued reports on BOLD. Zacks Investment Research upgraded Audentes Therapeutics from a hold rating to a buy rating and set a $28.00 price target for the company in a report on Tuesday, January 8th. Guggenheim upgraded Audentes Therapeutics from a neutral rating to a buy rating and set a $35.00 price target for the company in a report on Friday, January 11th. HC Wainwright reiterated a buy rating and issued a $33.00 price target on shares of Audentes Therapeutics in a report on Friday, January 11th. William Blair reiterated a hold rating on shares of Audentes Therapeutics in a report on Thursday, January 31st. Finally, Cowen reiterated a buy rating on shares of Audentes Therapeutics in a report on Thursday, January 31st. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and twelve have assigned a buy rating to the stock. Audentes Therapeutics currently has an average rating of Buy and an average price target of $39.38.

NASDAQ BOLD traded up $0.85 during trading hours on Tuesday, hitting $37.73. The company had a trading volume of 1,087,835 shares, compared to its average volume of 523,867. Audentes Therapeutics has a fifty-two week low of $17.95 and a fifty-two week high of $46.18. The company has a market cap of $1.66 billion, a P/E ratio of -11.10 and a beta of 1.85.

Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings results on Wednesday, February 27th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.08. During the same period last year, the company earned ($0.82) earnings per share. As a group, equities analysts predict that Audentes Therapeutics will post -3.8 earnings per share for the current fiscal year.

In other news, VP Suyash Prasad sold 10,000 shares of the firm’s stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $30.06, for a total transaction of $300,600.00. Following the completion of the sale, the vice president now directly owns 28,236 shares in the company, valued at $848,774.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Louis G. Lange sold 20,000 shares of the firm’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $36.00, for a total value of $720,000.00. Following the sale, the director now owns 306,099 shares of the company’s stock, valued at $11,019,564. The disclosure for this sale can be found here. Insiders have sold 51,000 shares of company stock valued at $1,650,600 over the last 90 days. Insiders own 6.60% of the company’s stock.

Several hedge funds have recently modified their holdings of BOLD. NumerixS Investment Technologies Inc lifted its position in shares of Audentes Therapeutics by 1,200.0% during the fourth quarter. NumerixS Investment Technologies Inc now owns 1,300 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 1,200 shares during the last quarter. Amundi Pioneer Asset Management Inc. bought a new position in shares of Audentes Therapeutics during the fourth quarter worth about $92,000. Great West Life Assurance Co. Can lifted its position in shares of Audentes Therapeutics by 96.0% during the fourth quarter. Great West Life Assurance Co. Can now owns 4,726 shares of the biotechnology company’s stock worth $97,000 after purchasing an additional 2,315 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in shares of Audentes Therapeutics by 46.1% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,280 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 1,983 shares during the last quarter. Finally, Legal & General Group Plc lifted its position in shares of Audentes Therapeutics by 34.5% during the fourth quarter. Legal & General Group Plc now owns 6,632 shares of the biotechnology company’s stock worth $141,000 after purchasing an additional 1,700 shares during the last quarter.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Article: What are the reasons investors use put options?

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.